To Evaluate the Safety and Efficacy of Poly-L-lactic Acid Implants for the Correction of Nasolabial Folds

A Prospective, Randomized, Evaluator/Subject-blinded, Single-center, Split-Face Controlled Clinical Study: To Evaluate the Safety and Efficacy of Poly-L-lactic Acid Implants for the Correction of Nasolabial Folds

The goal of this clinical trial is to evaluate the safety and effectiveness of a poly-L-lactic acid (PLLA) dermal implant for the correction of nasolabial folds. The study also aims to determine whether the investigational product (FUYANMEI Poly-L-Lactic Acid) is non-inferior to the control product (Sculptra).

The main questions it aims to answer are:

• Is the effectiveness rate based on the Wrinkle Severity Rating Scale (WSRS) at 6 months after injection for the investigational group non-inferior to that of the control group?
• How does the investigational product perform in terms of global aesthetic improvement as assessed by blinded evaluators and by subjects?
• What is the safety profile of the investigational product, including the incidence, severity, and relatedness of adverse events (AEs), serious adverse events (SAEs), and device deficiencies (DDs)?

Researchers will compare the investigational PLLA implant to an approved PLLA implant using a prospective, randomized, evaluator- and subject-blinded, single-center, split-face controlled study design. Approximately 121 eligible participants will be enrolled.

Participants will:

• Receive treatment with the investigational product and the control product according to the split-face design
• Be followed for 24 months after injection
• Return to the clinic at 1, 3, 6, 12, 18, and 24 months post-injection for follow-up visits
• Undergo blinded evaluator assessments of WSRS and Global Aesthetic Improvement Scale (GAIS)
• Complete subject self-assessments of GAIS and treatment satisfaction
• Be monitored throughout the study for adverse events, serious adverse events, and medical device deficiencies

Study Overview

• Status: Not yet recruiting
• Conditions: Nasolabial Fold Correction
• Intervention / Treatment: Device: FUYANMEI Poly-L-Lactic Acid; Device: Sculptra®

• Study Type: Interventional
• Enrollment (Estimated): 121
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Lai-San Wong, M.D.; Phone Number: 2424 +886-7-7317123; Email: laisan7@hotmail.com

Study Locations

• Taiwan
  • Kaohsiung City, Taiwan, 833401
    • Kaohsiung Chang Gung Memorial Hospital
    • Contact: Lai-San Wong, M.D.; Phone Number: 2424 +886-7-7317123; Email: laisan7@hotmail.com
    • Principal Investigator: Lai-San Wong, M.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Willing and able to provide written informed consent prior to any study-specific procedures.
2. Male or female subjects aged between 19 and 65 years.
3. Presence of bilateral nasolabial fold wrinkles with a Wrinkle Severity Rating Scale (WSRS) score of moderate (Grade 3) or severe (Grade 4) at baseline.
4. Willingness and ability to comply with all protocol-required follow-up visits and procedures.

Exclusion Criteria:

1. History of hypertrophic scarring or keloid formation.
2. Presence of active infection or dermatologic conditions at or near the intended injection site that may interfere with the evaluation.
3. Underwent major surgery within 3 months prior to study initiation.
4. Diagnosed with autoimmune diseases, malignancies, psychiatric disorders, or poorly controlled chronic medical conditions.
5. Prior treatment with or planned use of permanent dermal fillers at the intended injection site.
6. Prior treatment with or planned use of temporary fillers, collagen stimulators, or thread lifting at the injection site within 12 months prior to screening or during the study period.
7. Underwent or plans to undergo laser treatments to the mid- or lower face within 3 months prior to treatment or during the study period.
8. Underwent or plans to undergo ultrasound or radiofrequency skin tightening procedures to the mid- or lower face within 6 months prior to treatment or during the study period.
9. Known hypersensitivity to poly-L-lactic acid or any components of the investigational device, or any other significant allergy as deemed by the investigator to pose risk to the subject.
10. Planned surgeries or medications during the study period that may cause significant weight changes.
11. Pregnant or breastfeeding women, or women intending to become pregnant during the study period.
12. Participation in another interventional clinical trial that has not concluded within 30 days prior to screening, or plans to participate in another interventional clinical study during the course of this study.
13. Any other condition or situation that, in the opinion of the investigator, renders the subject unsuitable for study participation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: FUYANMEI Poly-L-Lactic Acid; Poly-L-Lactic Acid	Device: FUYANMEI Poly-L-Lactic Acid; Poly-L-Lactic Acid
Active Comparator: Sculptra®; Poly-L-Lactic Acid	Device: Sculptra®; Poly-L-Lactic Acid

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The responder rate based on the Wrinkle Severity Rating Scale (WSRS).	The WSRS responder rate at Month 6 post-injection was compared between the treatment and control groups. A WSRS responder was defined as a participant who achieved an improvement of at least 1 point in the WSRS score compared with baseline.	at Month 6 post-injection

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Wrinkle Severity Rating Scale (WSRS) scores	WSRS was assessed using a 5-point scale (1-5), with higher scores indicating greater wrinkle severity. Blinded evaluators assessed WSRS scores at baseline, immediately post-treatment (Day 0), and at Months 1, 3, 6, 12, 18, and 24 following injection.	at baseline, immediately post-treatment (Day 0), and at Months 1, 3, 6, 12, 18, and 24 post-injection
WSRS responder rates	WSRS responder rates assessed by blinded evaluators at baseline, Day 0, and Months 1, 3, 12, 18, and 24 post-injection. A WSRS responder was defined as a participant who achieved an improvement of at least 1 point in the WSRS score compared with baseline.	at baseline, Day 0, and Months 1, 3, 12, 18, and 24 post-injection
Change in nasolabial fold volume	Images were captured using a VECTRA H2 3D camera (Canfield Scientific) at a fixed distance from the subject's face under standardized lighting and background conditions. The resulting image files were analyzed for volumetric measurements using 3D imaging software. Changes in nasolabial fold volume from baseline (Day 0) were assessed at Months 1, 3, 6, 12, 18, and 24 using the three-dimensional imaging system.	at baseline, Day 0, and Months 1, 3, 6, 12, 18, and 24 post-injection
Global Aesthetic Improvement Scale (GAIS) scores	GAIS scores were measured using a 5-point scale (1-5), with lower scores indicating poorer improvement. Blinded evaluators assessed GAIS scores immediately post-treatment (Day 0) and at Months 1, 3, 6, 12, 18, and 24 after injection.	at immediately post-treatment (Day 0), and Months 1, 3, 6, 12, 18, and 24 post-injection
Subject-reported GAIS scores	Subject-reported GAIS scores at immediately post-treatment (Day 0), and Months 1, 3, 6, 12, 18, and 24 post-injection.	at immediately post-treatment (Day 0), and Months 1, 3, 6, 12, 18, and 24 post-injection
Subject-reported satisfaction scores	Subject-reported satisfaction was assessed at Months 1, 3, 6, 12, 18, and 24 post-injection. Participants rated their satisfaction with the treatment's safety and effectiveness using a questionnaire scored on a 5-point scale (1-5), where 5 indicated very high satisfaction and 1 indicated very low satisfaction.	at Months 1, 3, 6, 12, 18, and 24 post-injection
Incidence of Adverse Events (AEs)	The incidence rate of adverse events (AEs), expressed as a percentage, will be calculated based on subjects who reported AEs or whose AEs were observed by investigators. The incidence rate will be determined using the following formula: AE (%) = (number of subjects who experienced AEs in each group ÷ total number of subjects in each group) × 100. Adverse events will be assessed on the day of treatment and at Months 1, 3, 6, 12, 18, and 24 post-treatment.	at Day 0, Months 1, 3, 6, 12, 18, and 24 post-injection
Incidence of Serious Adverse Events (SAEs)	The incidence rate of serious adverse events (SAEs), expressed as a percentage, will be calculated based on subjects who reported SAEs or whose SAEs were observed by investigators. The incidence rate will be determined using the following formula: SAE (%) = (number of subjects who experienced SAEs in each group ÷ total number of subjects in each group) × 100. Adverse events will be assessed on the day of treatment and at Months 1, 3, 6, 12, 18, and 24 post-treatment.	at Day 0, Months 1, 3, 6, 12, 18, and 24 post-injection

Collaborators and Investigators

• Sponsor: SciVision Biotech Inc.

Study record dates

Study Major Dates

• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): June 28, 2027
• Study Completion (Estimated): March 31, 2028

Study Registration Dates

• First Submitted: January 6, 2026
• First Submitted That Met QC Criteria: January 6, 2026
• First Posted (Actual): January 15, 2026

Study Record Updates

• Last Update Posted (Actual): May 26, 2026
• Last Update Submitted That Met QC Criteria: May 21, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Nasolabial folds; Poly-L-lactic Acid
• Other Study ID Numbers: RDCT-NFFU

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No